Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

AstraZeneca Closes Busy Week With $11B in Revenue, New R&D Site
AstraZeneca Closes Busy Week With $11B in Revenue, New R&D Site
AstraZeneca topped off a very busy week with its first-quarter financial report, citing a total of $11.390 billion in revenue, a whopping increase of 60%.  ...
AviadoBio Gene Therapy Drug AVB-101 Gets Orphan Drug Tags in U.S. and EU
AviadoBio Gene Therapy Drug AVB-101 Gets Orphan Drug Tags in U.S. and EU
The FDA and the European Commission have granted AviadoBio Orphan Drug designations for its investigational gene therapy, AVB-101, for the treatment of patients with frontotemporal dementia (FTD). ...
FDA approves Epsolay cream for rosacea
FDA approves Epsolay cream for rosacea

The FDA has approved Epsolay cream for the treatment of inflammatory lesions of rosacea, Sol-Gel Technologies announced in a press release.

FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)
FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)
The U.S. Food and Drug Administration (FDA) approved VIVJOA™ (oteseconazole capsules), an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in female...
EU Approves Kapruvia for CKD-Associated Pruritus
EU Approves Kapruvia for CKD-Associated Pruritus
The European Commission has granted marketing authorization to Cara Therapeutics’ and Vifor Pharma’s Kapruvia (difelikefalin) for the treatment of patients with moderate-to-severe pruritus asso...
LianBio-Licensed Camzyos Gets FDA Approval for Treatment of Hypertrophic Cardiomyopathy
LianBio-Licensed Camzyos Gets FDA Approval for Treatment of Hypertrophic Cardiomyopathy
LianBio said Friday that Bristol Myers Squibb got U.S. Food and Drug Administration approval for Camzyos mavacamten capsules for the treatment of adults with symptomatic class II-III obstructive hy...
FDA grants fast track designation for SQZ’s solid tumour cell therapy
FDA grants fast track designation for SQZ’s solid tumour cell therapy
The US Food and Drug Administration (FDA) has granted Fast Track Designation for SQZ Biotechnologies’ lead cell therapy candidate, SQZ-PBMC-HPV, for treating HPV16+ advanced or metastatic solid t...
Many dietary supplements are tainted with hidden pharmaceuticals, study finds
Many dietary supplements are tainted with hidden pharmaceuticals, study finds
C. Michael White, Professor of Pharmacy Practice, University of Connecticut: Many over-the-counter dietary supplement products — especially those used for sexual enhancement and weight loss — a...
AstraZeneca’s and Daiichi Sankyo’s Enhertu Gains Another Breakthrough Therapy Designation
AstraZeneca’s and Daiichi Sankyo’s Enhertu Gains Another Breakthrough Therapy Designation
The FDA has granted AstraZeneca’s and Daiichi Sankyo’s antibody drug conjugate Enhertu (trastuzumab deruxtecan) a fifth Breakthrough Therapy designation for patients with unresectable or metas...
Pfizer and Biohaven Get EU Nod for Vydura Migraine Drug
Pfizer and Biohaven Get EU Nod for Vydura Migraine Drug

The European Commission has granted a marketing authorization for Pfizer’s and Biohaven Pharmaceutical’s oral migraine drug Vydura (rimegepant).

ViGeneron and Daiichi Sankyo to develop therapy for eye diseases
ViGeneron and Daiichi Sankyo to develop therapy for eye diseases

Follow-on collaboration between ViGeneron and Daiichi Sankyo allows the companies to create and validate vgAAV-based therapeutic candidates.

Study Suggests Late Stage Asset Could Delay Progression of Alzheimer’s Dementia
Study Suggests Late Stage Asset Could Delay Progression of Alzheimer’s Dementia
New research published in Neurology and Therapy suggests that treatment with anti-amyloid-beta protofibril antibody lecanemab (BAN2401) is estimated to slow the rate of disease progression in patie...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand